PIK3CA and breast carcinoma: The drug response model captured the relationship between the patient’s multi-omics profile and well-known breast cancer drugs such as Dabrafenib (r2 = 0.71), Gemcitabine (r2 = 0.59) and (AS605240) PI3K inhibitor (r2 = 0.75) among others with a high degree of confidence (Fig. 2).